Our data revealed that TIGIT/CD155 and PD1/PD-L1 checkpoint genes were significantly associated with GBM clinical outcome, thus we next analyzed RNA-seq data from these patients to identify genes and pathways which may be involved with TIGIT and PD1 expression in GBM. The gene discussed is PVR; the disease is glioblastoma.